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Abstract: Approximately half of all patients with non–small-cell 
lung cancer (NSCLC) develop brain metastases (BM) during the 
course of their disease, leading to significant challenges in treatment. 
Molecular targeted tyrosine kinase inhibitors have proven effective 
for patients with activating mutations in the epidermal growth fac-
tor receptor gene and chromosomal rearrangements involving the 
anaplastic lymphoma kinase gene. Despite their efficacy in sys-
temic disease control, their effectiveness in patients with BM is not 
well established. In this article, we review recent data on the use of 
epidermal growth factor receptor and anaplastic lymphoma kinase 
tyrosine kinase inhibitors for treatment of patients with NSCLC and 
BM. These data highlight the potential for meaningful disease con-
trol within the central nervous system and the inherent challenges in 
treating patients with NSCLC and BM.
Key Words: Anaplastic lymphoma kinase, Brain metastases, 
Epidermal growth factor receptor, Non–small-cell lung cancer, 
Targeted therapy.
(J Thorac Oncol. 2015;10: 1268–1278)
Non–small-cell lung cancer (NSCLC) comprises 80% to 85% of lung cancers, and the majority of patients present with 
advanced disease.1,2 Despite recent therapeutic advances, long-
term prognosis remains poor, with an estimated overall 5-year 
survival rate less than 5% for patients with metastatic disease.2
NSCLC is characterized by a high incidence of cen-
tral nervous system (CNS) metastases, with 30% to 50% of 
patients with NSCLC developing brain metastases (BM).3,4 
Patients with BM experience significant morbidity and 
reduced quality of life, often with neurological dysfunction 
and cognitive impairment,3–6 and a poor prognosis, with a 
median survival of 3 to 6 months.7,8
In the past decade, development of genotype-directed 
therapies for NSCLC has led to tumor response and progres-
sion-free survival (PFS) rates that are significantly higher 
than those associated with cytotoxic chemotherapy.9,10 Several 
tyrosine kinase inhibitors (TKIs) are established as effective 
therapies for NSCLC, particularly in patients with activating 
mutations in the epidermal growth factor receptor (EGFR) gene 
and chromosomal rearrangements involving the anaplastic lym-
phoma kinase (ALK) gene.11–14 Although the systemic efficacy 
of targeted agents is established, the intracranial efficacy of tar-
geted therapies in patients with CNS disease is not as well char-
acterized. This review summarizes data on the use of EGFR and 
ALK TKIs for the treatment of patients with NSCLC and BM 
and discusses novel strategies, including combination regimens 
with radiation therapy (RT) and other novel agents.
STANDARD THERAPY FOR CNS METASTASIS  
IN NSCLC
The CNS is considered a pharmacological sanctuary 
site for metastases, because the blood–brain barrier (BBB) 
restricts transit of chemotherapeutic agents into the brain 
parenchyma. Furthermore, many chemotherapeutic agents are 
substrates for drug efflux transporters, such as P-glycoprotein 
(P-gp), which is robustly expressed on the BBB, that further 
reduce intracellular drug levels and limit antitumor activity 
in the CNS.15 Currently, surgical resection and radiotherapy 
(whole-brain radiotherapy [WBRT], stereotactic radiosurgery 
[SRS], and stereotactic radiotherapy) are the most common 
treatments used in the management of BM. Although intra-
cerebrospinal fluid (CSF) therapy (i.e., intrathecal chemo-
therapy) can be used for patients with leptomeningeal disease, 
prognosis in this patient population is poor even with treat-
ment, with a median survival of 2 to 3 months.16
TARGETED THERAPIES FOR CNS  
METASTASES IN NSCLC
Use of molecular targeted therapies, particularly oral 
TKIs, has significantly improved the outcomes of NSCLC 
with identified molecular drivers. An analysis of clinical 
outcomes in patients enrolled in the Lung Cancer Mutation 
Consortium demonstrated that patients in whom a driver 
mutation was identified and who received corresponding 
targeted therapy exhibited improved survival compared with 
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those whose tumor did not harbor a driver mutation and those 
with a driver mutation who did not receive targeted therapy.17 
However, favorable outcomes might have been limited by the 
development of CNS disease, likely due to poor CSF penetra-
tion of the systemic therapy.18,19
Given the limited efficacy of standard chemotherapy 
regimens in CNS disease, there is a need to develop more 
effective approaches, especially for those whose tumors harbor 
actionable mutations and in whom prolonged systemic disease 
control is possible. Efforts are now aimed toward developing 
such therapies, e.g., EGFR and ALK TKIs, for treatment of 
NSCLC-related CNS metastases in patients whose tumors 
express the corresponding molecular alterations.
The BBB and Targeted Therapy 
for NSCLC and BM
The structure of the BBB is characterized by both tight 
and adherens junctions between endothelial cells that regulate 
the transit of nutrients, ions, and cells into the brain (Fig. 1). 
Molecules cross the BBB either by passive diffusion (usu-
ally restricted to small [molecular weight <400 Da], nonpo-
lar, and lipophilic compounds) or active transport (for polar 
compounds).20–22 The very low permeability of the brain 
microvascular endothelium restricts access of systemically 
administered agents into the CNS and brain lesions.
Although tumor growth and metastases can disrupt the 
BBB, the molecular size restrictions limit large-molecule 
biologics, including monoclonal antibodies, from crossing 
the BBB.20 Similarly, TKIs generally have poor BBB pen-
etration; for instance, imatinib CSF level has been reported 
to be only 3% of plasma levels in patients with chronic 
myeloid leukemia.24 Based on the pharmacokinetic (PK) 
data and the reduced efficacy of these agents in BM (dis-
cussed in the EGFR Inhibitors and ALK Inhibitors sections 
below), TKIs seem to have limited access to CNS metastases 
compared with extracranial metastases. A pharmacodynamic 
study using [¹¹C]-erlotinib positron emission tomography–
computed tomography in a patient with NSCLC and multiple 
BM treated with erlotinib suggested that erlotinib may accu-
mulate in some BM.25 However, there is evidence that drug 
efflux transporters, such as P-gp and breast cancer resistance 
protein, may limit BBB penetration of erlotinib and reduce 
its efficacy in the brain.26,27 Consequently, modulating drug 
efflux is one potential theoretical approach to increase TKI 
levels in BM, and there is evidence from preclinical studies 
suggesting that this may be an effective approach.28
EGFR Inhibitors
CNS metastasis in NSCLC with activating EGFR mutations. 
EGFR TKIs, such as erlotinib, gefitinib, and afatinib, have 
been established as effective first-line therapies in NSCLC 
harboring an activating EGFR mutation based on the several 
randomized trials.9,29,30 Their efficacy in systemic disease is 
well recognized, with response rates ranging from 70% to 80% 
and a median PFS rate of approximately 12 months, as well 
as significant and clinically relevant improvements in PFS and 
quality of life compared with chemotherapy. However, efficacy 
in CNS metastatic disease is less well established. Although 
CNS is a common site of relapse in patients receiving EGFR 
TKIs,31 data from retrospective studies indicate lower rates of 
CNS progression in patients with EGFR NSCLC who receive 
first-line TKIs than in those who receive chemotherapy, with 
a 12-month risk of CNS progression of 6% in the TKI group 
compared with 19% in the chemotherapy group.32
Data from retrospective studies suggest that patients with 
mutated EGFR NSCLC and BM may have better outcomes than 
patients whose tumor is EGFR wild type. Longer survival has 
been reported for these patients, possibly due to higher intra-
cranial response rates to radiation and intracranial activity of 
EGFR TKIs (Table 1). Studies show that treatment with EGFR 
FIGURE 1.  Schematic of the blood–
brain barrier. Reprinted with permis-
sion from Macmillan Publishers Ltd.23
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TKIs, such as gefitinib and erlotinib, can result in intracranial 
response in patients with EGFR mutation–positive NSCLC. A 
retrospective analysis of patients who were previously treated 
with erlotinib (n = 69) reported a time to progression within 
the brain of 11.7 months in patients with EGFR mutations 
compared with 5.8 months in those whose tumors were either 
EGFR wild type or unassessed, despite the fact that only 16% 
of patients with EGFR mutations had received WBRT versus 
85% of those in the control group.33 This and other similar ret-
rospective studies (Table 2) indicate that TKI therapy can result 
in clinically meaningful intracranial responses in some patients. 
Similarly, a prospective single-arm trial evaluated the role of 
second-line erlotinib in Asian patients (n = 48) with metastatic 
NSCLC and asymptomatic BM. In this patient population, 17% 
were known to be EGFR mutation positive, 31% EGFR wild 
type, and 52% of unknown status. Intracranial PFS was 10.1 
months, and overall PFS was 9.7 months in the overall popu-
lation. Among patients with EGFR mutations, overall PFS 
was 15.2 months, which was significantly longer than the 4.4 
months in patients with EGFR wild-type tumors (p = 0.02).34
Studies report that EGFR TKIs achieve therapeutic 
CSF concentrations, which accounts in part for intracranial 
responses (Table 3). Togashi et al.38 measured CSF concentra-
tions of erlotinib and its active metabolite, OSI-420, in patients 
with NSCLC and BM. Mean CSF penetration rates of erlo-
tinib and OSI-420 were 5.1% and 5.8% of total plasma con-
centration, respectively, which exceeds median half-maximal 
inhibitory concentration (IC
50
) values for EGFR inhibition. 
Additional studies have reported mean CSF penetration rates of 
2.8% to 4.4% for erlotinib, with slightly lower rates for gefitinib 
(1.1%–1.3%). Preclinical studies have also shown that EGFR 
TKIs are both substrates and inhibitors of drug efflux transport-
ers that limit CNS penetration (Table 3). These data and earlier 
PK studies39,40 support the concept that erlotinib achieves clini-
cally adequate concentrations in the CSF, although significantly 
lower compared with plasma concentration.
Given the limited CNS penetration of TKIs, some reports 
suggest that increasing the dose of the EGFR inhibitor may 
be an effective strategy for the treatment of CNS disease.53,54 
Previous studies have shown a linear correlation between 
plasma and CSF concentration of EGFR TKIs such as erlo-
tinib, suggesting that a higher dose may lead to higher CSF 
concentration and thereby improve CNS disease response.55 
A case report describes a patient with EGFR deletion 19 
mutation who experienced CNS tumor response using high-
dose gefitinib that achieved a therapeutic CSF concentration, 
suggesting that this may be a viable strategy in this patient 
population.53 However, a study of 10 patients who received 
pulsed-dose erlotinib 1000 to 1500 mg once weekly for CNS 
progression showed a modest response rate of 10%, with a 
median CNS PFS rate of 1.7 months.56 The benefit and poten-
tial toxicity of this strategy have not yet been evaluated in a 
prospective clinical trial.
There are other EGFR TKIs in development, and their 
efficacy in CNS disease is unknown at this time. Afatinib and 
dacomitinib are second-generation EGFR TKIs that cause irre-
versible inhibition of both EGFR and human EGFR 2 and 4 
(HER2 and HER4, respectively). Afatinib is currently approved 
for first-line therapy in patients with EGFR mutation–positive 
NSCLC. Its efficacy in CNS metastasis is unclear, and although 
there is a report of CNS response in a patient receiving a high 
afatinib dose,57 there is also a report of lack of CNS response.58 
A recent case report documented a partial response (PR) in 
the brain after dual treatment with afatinib and cetuximab in a 
patient with NSCLC who developed leptomeningeal carcino-
matosis,59 but this strategy should be evaluated in a prospective 
trial before routine clinical use as it is associated with signifi-
cant cutaneous toxicity.60 Dacomitinib is not yet approved but 
has shown activity as a first-line treatment in EGFR mutation–
positive patients with NSCLC, with an overall response rate 
(ORR) of 76% and median PFS of 18.2 months in a phase 2 
study that enrolled 45 patients with activating EGFR muta-
tions.61 An ongoing phase 3 trial is comparing dacomitinib with 
gefitinib as initial therapy in EGFR mutation–positive patients 
with NSCLC (NCT01774721); however, this study excludes 
patients with a history of brain or leptomeningeal metastases 
TABLE 1.  Retrospective Studies Evaluating Outcomes by EGFR Mutation Status in Patients with NSCLC and Brain Metastases
Efficacy Outcomes (EGFR Mutant vs. EGFR WT)
Study
No. of Patients 
(EGFR  
Mutant/WT)
Prior  
CNS-Directed 
Therapy
Patients Receiving 
EGFR TKI, EGFR 
Mutant/WT
Objective 
Radiographic 
CNS Response
Median Time  
to CNS 
Progression (mo)
Median  
Overall  
Survival (mo)
Cause of  
Death
Eichler et al. 35 93 (41/52) 83% WBRTa 78%/19%b Not evaluated by 
EGFR status
12.4 vs. 8.4  
(p = 0.39)
14.5 vs. 7.6c  
(p = 0.09)
62 deaths (7 CNS, 
39 systemic,d and 
16 both CNS and 
systemic)
Lee et al. 36 43 (30/13) 100% WBRT 50%/31%e 80% vs. 46%  
(p = 0.037)
21 vs. 12f  
(p = 0.009)
15 vs. 11  
(p = 0.049)
33 deaths (3 CNS, 
22 systemic, and 
8 other causes)
aEither alone (53%) or in combination with resection (22%) or SRS (8%).
bErlotinib or gefitinib received after diagnosis of brain metastases.
cFrom time of diagnosis of brain metastases.
dIncludes 54% (22/41) of patients with EGFR mutations and 33% (17/52) of patients with WT EGFR.
eErlotinib or gefitinib concurrent with WBRT.
fIntracranial radiographic progression-free survival.
CNS, central nervous system; EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer; TKI, tyrosine kinase inhibitor; SRS, stereotactic radiosurgery; WBRT, 
whole-brain radiotherapy; WT, wild type.
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(LM). A phase 2 study is evaluating the efficacy and safety of 
dacomitinib in cancer patients with progressive BM, including 
patients with primary lung cancer (NCT02047747). Although 
this study is not specifically aimed toward EGFR mutation–
positive NSCLC, it will allow further understanding of intra-
cranial activity and CNS PK of this agent.
There are emerging third-generation EGFR TKIs that 
show promising preliminary efficacy results in patients with 
acquired EGFR-resistance mutation such as T790M. Response 
rates of 58% and 64% have been reported with CO-1686 
and AZD9291, respectively, in patients who harbor T790M 
mutation.62,63 A case of CNS response with CO-1686 has 
been reported63; however, currently, the overall CNS response 
rate with this agent is unknown. Preclinical data indicate that 
AZD-9291 achieves significant exposure in the brain and is 
active against BM.64 In an ongoing phase 1 study, response in 
BM with AZD-9291 has been reported in some patients with 
EGFR mutation–positive NSCLC.64 HM61713, another third-
generation EGFR TKI, has shown activity in patients with 
EGFR mutation–positive NSCLC who had T790M mutation 
at baseline, although CNS activity with HM61713 has not yet 
been reported.65
TABLE 2.  Retrospective Studies of EGFR TKIs in NSCLC Patients with EGFR Mutations and Brain Metastases
Study
No. of Patients with 
EGFR Mutation
Prior CNS-Directed 
Therapy
Best Overall 
Response Progression-Free Survival Overall Survival
Heon et al.32 155 (101 EGFR TKIa  
and 54 Chemo)
89% WBRTb Not evaluated Disease progression (EGFR TKI vs. chemo) EGFR TKI 31.0 mo vs. 
chemo 29.8 mo  
(p = 0.131)
Rate of CNS progression: 33% vs. 48%
Time to CNS progression (mo): 56.0 vs. 31.6 
(p = 0.010)
Cumulative risk of CNS progression  
at 1 and 2 yr:
1 yr: 6% vs. 19%
2 yr: 21% vs. 32%
p = 0.026
Park et al.37 28c None PR: 83%
SD: 11%
6.6 mo 15.9 mo
aEleven patients received gefitinib and 90 patients received erlotinib as a first-line EGFR TKI.
bFor patients with brain metastases at the time of diagnosis of advanced NSCLC (n = 24 in the EGFR TKI group and n = 12 in the chemo group). A small number of these patients 
received WBRT in combination with surgical resection.
cTwenty-two patients received gefitinib and six patients received erlotinib as first-line EGFR TKI.
CNS, central nervous system; chemo, chemotherapy; EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer; PR, partial response; SD, stable disease; TKI, 
tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.
TABLE 3.  CNS Penetration of Targeted Therapies for Patients with NSCLC and Brain Metastases
Agent
Molecular  
Formula/Weight  
(Da)a
Interactions with Efflux 
Transporters  
(BCRP and P-gp) CNS Penetration
Substrate Inhibitor
CSF Penetration  
Rate (%)b
Restricted Penetration 
Because of Drug Efflux 
Transporters (BCRP/P-gp)c
Erlotinib C
22
H
23
N
3
O
4
/429.90 Yes41 Yes42 Low/moderate
5.1 ± 1.9 (n = 4)38
2.8 ± 0.5 (n = 9)43
4.4 ± 3.2 (n = 6)44
Yes26,27
Gefitinib C
22
H
24
ClFN
4
O
3
/446.9 Yes45 Yes46 Low
1.3 ± 0.7 (n = 22)47
1.1 ± 0.4 (n = 8)43
Yes45
Afatinib C
24
H
25
ClFN
5
O
3
/485.9 Yes48 Yes48 Unknown Unknown
Crizotinib C
21
H
22
Cl
2
FN
5
O/450.3 Yes28 Yes49 Low
0.26 (n = 1)19
Yes28
Ceritinib C
28
H
36
ClN
5
O
3
S/558.1 Unknown Unknown 1550,d Unknown
Alectinib C
30
H
34
N
4
O
2
/482.6 No51,e Unknown 8752 Unknown
aObtained from the PubChem Compound Database (http://www.ncbi.nlm.nih.gov/pccompound).
bAssessed using blood and CSF samples from patients with NSCLC; mean ± standard deviation.
cBased on the nonclinical studies using mouse models.
dBlood-to-brain exposure (AUC
inf
) ratio in rats.
eAlectinib was not transported by P-gp in cell transport assay, suggesting it as a poor or non-P-gp substrate.
AUC
inf
, area under the plasma concentration-time curve from time 0 to infinity; BCRP, breast cancer resistance protein; CNS, central nervous system; CSF, cerebrospinal fluid; 
NSCLC, non–small-cell lung cancer; P-gp, P-glycoprotein.
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EGFR inhibitors and RT. One important question is 
whether EGFR inhibitors could be used concurrently with 
RT to improve intracranial efficacy. The role of EGFR 
inhibitors in CNS disease has been evaluated in combination 
with radiation because preclinical studies have shown that 
EGFR overexpression is associated with radioresistance in 
murine models,66 and EGFR blockade has shown to increase 
radiosensitivity in in vitro studies.67
A retrospective analysis of 63 patients with BM from 
lung adenocarcinoma (46 with EGFR mutations and 17 with 
wild-type EGFR) who were treated with WBRT (n = 45) or 
concurrently with an EGFR TKI (n = 18) found that EGFR 
TKIs and EGFR mutation were independently associated with 
response to WBRT at 1 month after radiation, suggesting that 
EGFR TKIs increased sensitivity to WBRT.68 In this study, 
patients who received WBRT with an EGFR TKI had a bet-
ter response rate (67%) than those who received only WBRT 
(39%). This hypothesis was examined in a phase 2 single-arm 
trial (n = 40) that evaluated the combination of WBRT and 
erlotinib in NSCLC patients with BM regardless of EGFR 
mutation status. This study reported an ORR of 86% and an 
overall median survival of 11.8 months, which was signifi-
cantly higher than survival reported in the literature.69 Among 
patients with known EGFR mutational status (n = 17), patients 
with an EGFR-activating mutation (n = 9) exhibited signifi-
cantly higher ORR (89% versus 63%) and survival (19.1 ver-
sus 9.3 months) than patients with no EGFR mutations (n = 8). 
The combination therapy was well tolerated, and rash was the 
most common toxicity. There were no grade 4 or 5 toxicities, 
and there was no evidence of worse erlotinib-induced rash 
within the radiation port. In contrast to the earlier study, in a 
Radiation Therapy Oncology Group phase 3 trial of WBRT 
plus SRS with either temozolomide or erlotinib in unselected 
NSCLC patients with one to three BM, the addition of temo-
zolomide or erlotinib seemed to have a deleterious effect on 
time to progression and survival, although this was not sta-
tistically significant.70 Similarly, no significant benefit was 
observed with the addition of gefitinib to WBRT in a similar 
phase 2 randomized trial in unselected patients with BM by the 
Swiss Group for Clinical Cancer Research.71 The aforemen-
tioned studies indicate that the benefit and toxicity of EGFR 
TKIs in combination with WBRT are unclear at this time and 
need additional definitive studies, and until these studies are 
completed, it is not recommended that TKIs be combined with 
RT outside of clinical trials. Currently, there is an ongoing 
randomized phase 3 trial of WBRT with or without erlotinib 
(NCT01887795) that may clarify the role of erlotinib in com-
bination with WBRT (Table 4).
The studies described earlier suggest that EGFR TKI 
monotherapy may be a reasonable strategy for EGFR muta-
tion–positive patients with asymptomatic CNS disease who 
are TKI naive. Some studies suggest that erlotinib may have 
better CSF penetration than gefitinib43; thus, erlotinib may be 
preferred over gefitinib if TKI monotherapy is used upfront 
for asymptomatic patients with BM. The role of concurrent 
EGFR TKI and WBRT has not been established at this time, 
and more studies are needed to better delineate the benefit 
and safety of this strategy. As development of third-genera-
tion EGFR TKIs progresses, patients with EGFR mutation–
positive NSCLC will have increasing treatment options that 
will result in prolonged systemic disease control. Studies 
TABLE 4.  Ongoing Phase 2–3 Trials of Targeted Therapies for the Treatment of NSCLC Brain Metastases
Agent NCT Identifier Phase Description Status
Studies of EGFR TKIs in patients with NSCLC brain metastases
 Erlotinib NCT01887795 3 WBRT vs. erlotinib with concurrent WBRT as first-line treatment in patients 
with multiple brain metastases
Recruiting
NCT01763385 2 Erlotinib with concurrent brain radiotherapy and secondary brain radiotherapy 
after recurrence with erlotinib
Recruiting
NCT00871923 2 Erlotinib with concurrent WBRT in patients with brain metastases Ongoing, not recruiting
 Gefitinib NCT01951469 2 Gefitinib ± pemetrexed/cisplatin in patients with brain metastases Recruiting
Studies of ALK TKIs in ALK-positive NSCLC that include patients with asymptomatic/stable brain metastases
 Crizotinib NCT02075840 3 Alectinib vs. crizotinib in treatment-naive patients Not yet recruiting
NCT01639001 3 Crizotinib vs. chemo in previously untreated East Asian patients Recruiting
NCT02134912 2 Pemetrexed ± crizotinib in patients who have progressed after crizotinib Not yet recruiting
NCT00932451 2 Crizotinib in ALK-positive NSCLC Recruiting
 Ceritinib NCT01828112 3 Ceritinib vs. chemo in patients previously treated with chemo and crizotinib Recruiting
NCT01828099 3 Ceritinib vs. chemo in previously untreated patients Recruiting
NCT01685060 2 Ceritinib in patients previously treated with chemo and crizotinib Ongoing, not recruiting
NCT01685138 2 Ceritinib in crizotinib-naive patients Ongoing, not recruiting
NCT02040870 1/2 Ceritinib in Chinese patients previously treated with crizotinib Recruiting
 Alectinib NCT01871805 1/2 Alectinib in patients previously treated with chemo and crizotinib Recruiting
NCT01801111 1/2 Alectinib in patients who have failed crizotinib Recruiting
 AP26113 NCT02094573 2 AP26113 in patients previously treated with crizotinib Recruiting
ALK, anaplastic lymphoma kinase; chemo, chemotherapy; EGFR, epidermal growth factor receptor; NCT, National Clinical Trial; NSCLC, non–small-cell lung cancer; TKI, 
tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.
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evaluating the combination of second- and third-generation 
EGFR inhibitors with brain radiotherapy (SRS or WBRT) 
are needed to fully explore their potential in the treatment of 
patients with NSCLC and BM. Therefore, treatment strategies 
with effective CNS disease control will be crucial in improv-
ing the overall outcomes in this patient population.
ALK Inhibitors
CNS metastasis in ALK-positive NSCLC. The ALK gene 
encodes a receptor tyrosine kinase that is activated in a 
subset of patients with NSCLC and other tumors, and ALK 
inhibitors such as crizotinib have shown to be effective in 
tumor response and disease control.10,72,73 Despite an initial 
response, many patients with ALK-positive NSCLC will 
eventually progress, with the CNS being a common site of 
initial disease progression, including intramedullary spinal 
cord metastases and leptomeningeal carcinomatosis.74 In a 
retrospective analysis of patients with ALK-positive NSCLC 
receiving crizotinib treatment in phase 1 and 2 trials, 46% 
of patients progressed first in the CNS.31 Also, the overall 
incidence of BM in patients with ALK-positive NSCLC is 
high, evident in several recent trials in which 35% to 50% 
of enrolled patients had stable or asymptomatic BM.10,75 This 
has created the need for a greater understanding of both the 
CNS activity of currently approved ALK inhibitors and the 
potential of those currently in development.
Crizotinib. Crizotinib is an adenosine triphosphate–
competitive small-molecule inhibitor of ALK, MET, and ROS1 
tyrosine kinases.76 In vitro, crizotinib exhibited dose-dependent 
inhibition of nucleophosmin–ALK xenograft models and 
reduced signaling of downstream effectors and therefore was 
further evaluated for clinical efficacy.77 Crizotinib was the 
first ALK inhibitor approved for treatment of patients with 
metastatic NSCLC whose tumors harbor ALK rearrangement. 
Approval was based on the pivotal phase 1 trial of crizotinib 
in patients with ALK-positive NSCLC who received previous 
chemotherapy, in which ORR was 61% with a median duration 
of response of 49.1 weeks.78 The efficacy of crizotinib was 
confirmed in subsequent randomized trials that compared 
it with chemotherapy in first- and second-line settings.10,79 
However, it is important to note that patients develop resistance 
to crizotinib within 8 to 11 months.10,78,79
The brain is the most common site for new lesion devel-
opment in patients who develop crizotinib-resistant ALK-
positive NSCLC. In the previously mentioned phase 1 study, 
149 patients with ALK-positive NSCLC were treated with 
crizotinib. Of 39 patients who derived clinical benefit from 
and continued to receive crizotinib for more than 2 weeks after 
disease progression, the most common site of disease progres-
sion was the brain (n = 10), which was the only site of ini-
tial disease progression. The authors speculated that this may 
have been because of PK failure within the CNS as a sanctu-
ary site.18 Similarly, a retrospective study of 38 ALK-positive 
patients showed that among those progressing on crizotinib, 
46% had first progressed in the CNS.31
In contrast, retrospective analyses of clinical trial data 
suggest that clinically meaningful disease control may be 
achieved with crizotinib in patients with CNS metastasis. In 
the second-line phase 3 randomized trial of crizotinib versus 
chemotherapy (PROFILE 1007), approximately one-third of 
patients had BM. Subgroup analysis showed that the hazard 
ratio for PFS was 0.67 in patients with BM versus 0.43 in 
those without BM, indicating a lower but still clinically mean-
ingful benefit in patients with BM treated with crizotinib.80 
In addition, a pooled analysis of a previous single-arm phase 
2 trial (PROFILE 1005) and second-line randomized trial 
(PROFILE 1007) of crizotinib showed that the 12-week intra-
cranial disease control rate was 56% among the 109 patients 
with untreated asymptomatic BM compared with 62% among 
the 166 patients with previously treated BM.80 In the small 
subset of patients with CNS target lesions at baseline, the con-
firmed intracranial response rate was 18% in patients who did 
not receive brain radiotherapy and 33% in patients with previ-
ously treated BM (Table 5). The above retrospective analy-
ses suggest that CNS disease control may be achievable with 
crizotinib initially, but this likely is not durable as patients 
eventually demonstrate progression.
Crizotinib has been considered to have lower efficacy in 
BM compared with other sites of metastasis because of poor 
penetration across the BBB.83 PK studies are limited, but a case 
report of a patient with ALK-positive NSCLC who was treated 
with crizotinib and subsequently developed BM reported drug 
levels in both plasma and CSF. Crizotinib level was 237 ng/
ml in plasma versus 0.62 ng/ml in CSF, suggesting that the 
higher rate of CNS progression compared with systemic 
progression could result from a low plasma to CSF ratio.19 
Low CSF levels are seen with other TKIs, including gefitinib 
and erlotinib, although the penetration rate with EGFR TKIs 
seems to be higher compared with that of crizotinib (Table 3). 
This suggests that approaches to increase the concentration of 
crizotinib within the CNS or use of other ALK inhibitors with 
greater CSF penetration may have therapeutic potential.
Potential future directions for crizotinib include 
chemical modification to improve bioavailability, develop-
ment of an intra-CSF formulation, and combined modal-
ity approaches.83 Crizotinib is a P-gp substrate for efflux 
pumps, such as the ABCB1 transporter, which act to reduce 
TABLE 5.  Intracranial Response Rates with ALK Inhibitors
Study Agent
No. of Patients  
with NSCLC BM 
at Baseline
Intracranial 
ORR
Costa et al.80 Crizotinib 22a
18b
18%c
33%c
Shaw et al.81 Ceritinib 74 34.5%d
Gadgeel et al.52 Alectinib 21 33%e
Gettinger et al.82 AP26113 10 60%f
aPatients with previously untreated BM and CNS target lesions at baseline.
bPatients with previously treated BM and CNS target lesions at baseline.
cBased on confirmed CNS responses.
dConfirmed responses among the 29 patients with measurable BM at baseline by MRI.
eBased on confirmed CNS responses. An additional 19% of patients had unconfirmed 
responses in the CNS.
fBased on independent radiological review of patients with untreated or progressing BM.
ALK, anaplastic lymphoma kinase; BM, brain metastases; CNS, central nervous 
system; MRI, magnetic resonance imaging; NSCLC, non–small-cell lung cancer; ORR, 
objective response rate.
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its intracellular concentration.49,84 Combination of crizotinib 
and elacridar (inhibitor of ABCB1/ABCG2 efflux transport-
ers) was shown to increase plasma and brain concentrations 
of crizotinib in mice,28 and this may be a promising approach 
in patients with ALK-positive NSCLC. Other approaches 
include use of high-dose crizotinib with WBRT85 and use 
of high-dose crizotinib with chemotherapy,86 but these 
approaches remain investigational and need further evalua-
tion in clinical trial settings.
Ceritinib. Ceritinib (LDK378) was recently approved by 
the U.S. Food and Drug Administration for treatment of 
patients with ALK-positive metastatic NSCLC with disease 
progression on or who are intolerant to crizotinib. This 
agent is a next-generation ALK inhibitor that is selective 
for ALK at low concentrations (IC
50
, 0.15 nM) in vitro.87 In 
ALK-positive NSCLC xenograft models, ceritinib exhibits 
antitumor activity, including in tumors resistant to crizotinib, 
and can overcome a variety of common crizotinib resistance 
mutations such as L1196M, G1269A, I1171T, and S1206Y.87 
A recent phase 1 trial (ASCEND-1) demonstrated clinical 
efficacy of single-agent ceritinib in patients with ALK-
positive advanced solid tumors, approximately half of whom 
had BM at baseline.75,88 The ORR was 62% in patients with 
NSCLC treated with 750 mg ceritinib daily, with responses 
seen in both crizotinib-pretreated and crizotinib-naive 
patients. Median PFS was 18.4 months in ALK inhibitor–
naïve patients and 6.9 months in crizotinib-pretreated 
patients. Responses were observed independent of type of 
ALK resistance mutation.
Responses were also seen in untreated CNS lesions 
in patients previously treated with crizotinib, with some 
responses occurring after 6 weeks of therapy. In the afore-
mentioned trial, 124 had BM at baseline, 74 had magnetic 
resonance imaging scans, and 29 of these were measurable 
lesions.81 Ceritinib was associated with objective intracranial 
responses in 10 (34.5%) of these 29 patients (Table 5); another 
5 of 45 patients with nonmeasurable brain lesions showed 
complete response after ceritinib treatment. The response was 
durable, with a median duration of response of 6.9 months in 
patients with previous ALK inhibitor therapy, and the median 
duration of response had not been reached in patients who 
were ALK inhibitor naive at the time data were reported. In 
addition, a recent case report documented prolonged stabi-
lization of carcinomatous meningitis associated with BM 
after treatment with ceritinib in a patient with ALK-positive 
NSCLC who developed CNS progression after more than 2 
years on crizotinib therapy.89
The efficacy and safety of ceritinib in patients with 
ALK-positive NSCLC and BM will be further evaluated 
in ongoing trials (Table 4). The ASCEND-2 phase 2 trial 
(NCT01685060) is evaluating ceritinib in patients with ALK-
positive NSCLC previously treated with chemotherapy and 
crizotinib; a secondary end point in this trial will be over-
all intracranial response rate. The ASCEND-5 phase 3 trial 
(NCT01828112) will randomize patients who have received 
previous chemotherapy and crizotinib to either ceritinib or 
chemotherapy (docetaxel or pemetrexed). Both trials will 
enroll patients with BM who are asymptomatic and are 
neurologically stable. A prospective trial assessing intracra-
nial responses and the efficacy of ceritinib in ALK-positive 
NSCLC patients with BM and leptomeningeal disease is 
planned to start patient accrual.
Other ALK inhibitors in development. Alectinib is another 
second-generation TKI with activity against ALK in vitro and 
in vivo (IC
50
, 1.9 nM).90 Compared with crizotinib, alectinib 
is a less-effective substrate for drug efflux proteins such as 
P-gp,84 and, consequently, alectinib may be better able to 
achieve effective intra-CSF drug levels. A phase 1/2 trial 
of alectinib reported a PR of 54.5% among 44 evaluable 
patients with crizotinib-resistant advanced NSCLC, among 
whom 21 had BM at baseline.52,84 Among the patients with 
CNS metastases, 11 (52%) had an objective response in the 
CNS (7 [33%] confirmed responses and 4 [19%] unconfirmed 
responses; Table 5), and among the 4 patients with no 
previous radiotherapy, 3 achieved response (2 had complete 
response, 1 PR, and 1 stable disease).84 Alectinib has also 
demonstrated activity against LM in ALK-positive NSCLC 
patients previously treated with crizotinib and ceritinib. One 
report documented a complete response with alectinib lasting 
for more than 15 months in patient with ALK-positive NSCLC 
who developed diffuse leptomeningeal carcinomatosis after a 
prolonged response to crizotinib,91 whereas another described 
clinical and radiographic improvements in three of four 
patients who developed LM after treatment with crizotinib 
and ceritinib.92 An ongoing phase 3 trial (NCT02075840) 
will compare crizotinib and alectinib in treatment-naive 
patients with advanced NSCLC and will evaluate time to CNS 
progression as a secondary end point. A second phase 3 trial 
is evaluating alectinib versus chemotherapy in chemotherapy-
naive patients; intracranial and extracranial disease control 
rate will be assessed as secondary end points.
AP26113 is a selective inhibitor of activated forms of 
ALK, EGFR, and ROS1, but not wild-type EGFR, which can 
overcome crizotinib resistance mutations.93–95 A phase 1/2 
trial assessed the safety and activity of AP26113 in patients 
with advanced malignancies that harbor ALK, EGFR, or ROS1 
abnormalities. Among patients with ALK-positive NSCLC 
who received previous crizotinib, response rate was 63% 
(24/38). Response in BM was seen in 6 of 10 (60%) ALK-
positive patients with untreated or progressing CNS lesions at 
baseline, including 4 with undetectable BM after AP26113.82
A number of other second-generation ALK inhibitors 
are in development, all with limited or in some cases no clini-
cal data, including ASP3026,96 TSR-011,97 X-396,98 RXDX-
101,99 and CEP-28122100 and CEP-37440.101 Several of these 
agents have shown early clinical activity in ALK-positive 
NSCLC, with ORRs of 44% with ASP3026 (7 PRs in 15 
patients), 60% with TSR-011 (3 PRs in 5 patients), and 83% 
with X-396 (5 PRs in 6 patients treated at doses ≥200 mg). 
CNS responses were observed in two patients treated with 
X-396 (one crizotinib naive and one crizotinib pretreated).
Preclinical data with PF-06463922, a highly-potent 
third-generation ALK and ROS1 inhibitor, suggest that this 
agent may have substantial CNS activity. PF-06463922 
has demonstrated significant brain exposure, supported 
by in vitro data indicating that this compound is not a 
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substrate for the drug efflux transporters P-gp and breast 
cancer resistance protein.102 A phase 1/2 trial in patients 
with ALK-positive and ROS1-positive NSCLC that includes 
intracranial ORR as a primary end point is ongoing 
(NCT01970865).
The studies described earlier demonstrate that the CNS 
is a frequent site of disease progression in patients with ALK-
positive NSCLC on crizotinib, likely due to inadequate CSF 
penetration. Next-generation ALK inhibitors, such as ceri-
tinib, alectinib, and AP26113, have been shown to be effective 
in patients whose disease progressed on crizotinib, including 
those with active CNS disease. However, their clinical effi-
cacy in the CNS has not yet been fully characterized. Future 
investigations will need to clarify optimal sequencing of the 
above TKIs in patients with CNS disease and whether these 
will be effective and safe in multimodality therapies, such as 
in combination with radiation.
ALK inhibitors and RT. Recent studies suggest that 
local ablative therapy (LAT) can be used to extend 
the clinical benefit of crizotinib in those who develop 
nonleptomeningeal CNS and limited (one to four sites) 
extra-CNS oligoprogressive disease.31,103 In the study by 
Weickhardt et al.,31 patients with nonleptomeningeal CNS 
and limited systemic progression who received LAT had a 
longer duration of TKI therapy compared with those who 
were not suitable for LAT with an additional 6-month 
disease control on TKI.
An ongoing clinical trial is evaluating ALK inhibitors 
and other targeted therapies in combination with stereotac-
tic brain treatment in patients with stage IV oncogene-driven 
(EGFR, ALK, or ROS1) NSCLC (NCT02314364). In this 
study, eligible patients include those with up to four BM who 
will receive stereotactic radiotherapy while continuing the 
appropriate TKI therapy.
Emerging Targeted Therapies in NSCLC
In addition to EGFR and ALK genetic aberrations, 
there are emerging molecular targets for which genotype-
directed therapies are in development. Genetic abnormalities, 
such as ROS1 and RET rearrangements and mutations in the 
HER2 and BRAF genes, are emerging as clinically important 
molecular targets, and active research is ongoing to identify 
effective targeted therapies for these molecular subtypes.17 
Currently, there are no data regarding the efficacy of these tar-
geted therapies in patients with BM whose tumors harbor the 
aforementioned uncommon aberrations.
CONCLUSION
The advent of targeted therapies has improved disease 
control and survival of a subset of NSCLC patients with an 
identified driver mutation. These targeted therapies result 
in excellent systemic disease control, but their efficacy is 
often limited by CNS disease progression. The role of first-
generation TKIs such as erlotinib and crizotinib in CNS 
metastasis is modest; however, limited CSF penetration has 
been observed, and corresponding low rates of intracranial 
responses also have been reported. Therefore, initial therapy 
with either erlotinib or crizotinib is a reasonable approach 
in patients with small, asymptomatic CNS metastases that 
harbor the appropriate targetable mutation. In patients with 
ALK-positive NSCLC, early data from clinical trials of sec-
ond-generation ALK inhibitors have shown promising CNS 
responses, including in patients with leptomeningeal dis-
ease. There are ongoing prospective studies that will further 
elucidate whether these novel agents will be more active or 
effective in ALK-positive NSCLC patients with CNS dis-
ease. Surgical resection and RT remains the cornerstone of 
treatment for symptomatic CNS disease, and there are ongo-
ing trials to determine the role of targeted therapies in com-
bination with these modalities. Although systemic therapy 
in metastatic NSCLC has changed dramatically in the past 
decade with the development of effective targeted therapies, 
continued and further efforts are needed to develop effective 
therapies specifically for CNS disease to improve the out-
come of advanced disease in patients with NSCLC.
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